Health Technology · Pharmaceuticals: Major · NSE: PPLPHARMA · data 2026-10-09
Piramal Pharma Limited
Health check: Weak (2.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹196.88
Market cap
₹26,154 cr
P/E
—
P/B
—
ROE
-4.0%
ROCE
1.3%
Debt / equity
0.7
Dividend yield
0.07%
1-year return
1.0%
52-week high
₹231.93
52-week low
₹132.3
Operating margin
1.7%
Growth
| Revenue (last 12 months) | ₹9,205 cr |
| Net profit (last 12 months) | ₹-314 cr |
| Sales growth, 3 years (yearly) | 7.8% |
| Profit growth, 3 years (yearly) | — |
Chart patterns
- Double top — breakdown (key level ₹198.86)
- Descending triangle — breakdown (key level ₹198.86)
- Head and shoulders — breakdown (key level ₹198.86)
Similar companies
Emcure Pharmaceuticals Limited (EMCURE) · Wockhardt Limited (WOCKPHARMA) · Neuland Laboratories Ltd. (NEULANDLAB) · Acutaas Chemicals Ltd (ACUTAAS) · Shilpa Medicare Limited (SHILPAMED)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PPLPHARMA in NSE Scanner →